BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261202T160000
DTEND;TZID=America/New_York:20261202T173000
DTSTAMP:20261028T180147Z
CREATED:20261005T222447Z
LAST-MODIFIED:20261028T180147Z
UID:3649-1796227200-1796232600@lifescievents.com
SUMMARY:Kazia Therapeutics Virtual Event: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
DESCRIPTION:Join Kazia Therapeutics for a virtual event featuring management’s overview of NDL2\, the Company’s novel nuclear PD-L1 protein degrader designed to address mechanisms of immunotherapy resistance in advanced solid tumors\, with an initial focus on metastatic breast cancer and colorectal cancer. NDL2 represents a potentially first-in-class approach within the emerging field of protein degradation\, a therapeutic category with no known compounds currently in clinical development. \nThe event will provide an overview of NDL2 and its optimized bicyclic peptide designed to selectively degrade disease-associated nuclear PD-L1 protein and restore the body’s natural anti-tumor immune response. The PD-L1 protein plays an important role in regulating the immune system\, but some cancer cells take advantage of this natural mechanism to evade immune detection and resist treatment. Kazia is leading a new frontier with Targeted Protein Degradation (TPD)\, exploiting naturally occurring protein degradation pathways to disrupt critical cellular processes. \nA live question and answer session will follow the formal presentations. \nDisclaimer: NDL2 is an investigational\, preclinical-stage therapeutic candidate and has not been approved for clinical use. Statements regarding its potential therapeutic benefits and future development are forward-looking and subject to risks and uncertainties. Additional information regarding these risks is available in Kazia Therapeutics’ filings with the U.S. Securities and Exchange Commission. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/kwt10h/.
URL:https://lifescievents.com/event/kwt10h/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/10/Events-Banners_2-33.png
END:VEVENT
END:VCALENDAR